Health

Health insurance news usually arrives like corporate weather: a “strategic decision,” a “realignment,” everybody pretend it is just numbers. But when you read it the way people live it, it sounds more like a courthouse hallway: paper, old carpet, and that quiet panic of someone clutching forms like a life raft.

What Baylor Scott & White Health Plan says it is doing

In plain English: Baylor Scott & White Health Plan says it intends to exit the Texas Medicaid Managed Care Program at the end of August 2026 and discontinue its individual ACA marketplace plans after December 31, 2026, pending regulatory approval.

• People affected: about 225,000 Texans (about 125,000 Medicaid members and roughly 100,000 individual marketplace enrollees).
• Jobs affected: the plan says 321 jobs across Texas are being impacted.

The health system says its hospitals and clinics will still accept patients who have Medicaid and marketplace coverage. That is true and also confusing, because America loves naming two different entities the same thing and then acting shocked when patients cannot decode the org chart at the pharmacy counter.

The liberty ledger: who loses choice, and who gets to call it “choice”

This is not a provider slamming the door on Medicaid patients. It is an insurer backing out of two markets, and telling people they will be reassigned, re-shopped, or reprocessed. The business calls it a transition. Patients experience it as a trust fall with a deadline.

Medicaid members are least able to absorb disruption: chronic conditions, disability, pregnancy, complex pediatric care, mental health needs, unpredictable work hours, transportation headaches. Even when continuity is promised, people still do the unpaid labor: new cards, new portals, new call trees, new denials, new surprises.

Marketplace enrollees already live with narrow networks and the annual ritual of asking whether they can afford to be a person with a body next year. A plan ending after December 31, 2026 is not “flexibility.” It is moving day.

The tradeoff, the Orwell check, and the Paine test

One report cites the plan pointing to the state Medicaid procurement decision and marketplace “complexities.” Tradeoff: administrative order for the state, churn for patients. Orwell check: “complexities” is the soft word that means someone will lose time, money, or access. “Impacting jobs” is antiseptic, too; jobs are lost or changed.

Paine test: does this expand liberty, or concentrate power? When a plan exits, remaining plans gain share, the state gains reassignment power, and the patient gets a packet explaining how to keep the same doctor if the new plan agrees they are allowed to.

Guardrails that should be non-negotiable

If exits like this are approved, regulators and lawmakers should insist on public, enforceable guardrails: continuity of care with teeth for active treatment; timelines designed for patient reality; plain-language disclosure of reassignment rules and options; and clear, readable rules on privacy and data-sharing during transitions. Sunlight beats euphemism, every time.

If 225,000 people can be told to switch coverage because the paperwork got complicated, what exactly is the plan for protecting patients when the next exit notice arrives?

The committee-room aroma is scorched coffee plus printer toner, which fits, because American health care is still held together by clipboards, fax machines, and a prayer. Every few years, someone arrives with a glossy “modernization” brochure. The brochure is shiny. The guardrails are usually optional.

What CMS announced (dates and basics)

CMS is pushing a major bet: the ACCESS Model, a 10-year, voluntary effort meant to expand technology-supported care for people with Medicare, especially for chronic conditions.

• CMS says more than 150 organizations have been accepted for the launch.
• CMS has extended the initial application deadline to May 15, 2026.
• The model is set to start July 5, 2026.

CMS also notes that being on the accepted list is not automatic participation. Organizations still have to complete requirements and get final CMS approval.

ACCESS is aimed at conditions including high blood pressure, diabetes, chronic pain, and depression, and CMS highlights that many accepted organizations have not previously served Medicare beneficiaries.

“Kill the clipboard,” but watch the back door

Alongside ACCESS, CMS is marketing a broader HealthTech Ecosystem to end the clipboard era, touting shared standards for identity, security, and interoperability. It has also rolled out a Medicare App Library concept and patient-facing apps intended to streamline check-in and data sharing.

I am not here to defend the fax machine. I would like to see it indicted. But digital convenience is not automatically a civil-liberties win. Sometimes it is just a faster way to do the wrong thing.

The Paine test and the Orwell check

The Paine test: does this expand liberty, or concentrate power? If ACCESS works as promised, it could mean more convenient care, more options, and less bureaucratic warfare for Medicare beneficiaries, with clinicians spending less time on forms and more time treating humans.

But paper is locally annoying. Digital systems scale. They replicate. They get queried. Once health data becomes a high-speed asset, everyone who touches it starts acting like they deserve a slice.

The Orwell check: “patient-centered” can become a euphemism for “data-centered.” CMS says the ecosystem is about giving patients control. Good. Now define control: a real right to say no without losing access to care, meaningful limits on secondary uses, clear separation from unrelated enforcement or commercial surveillance, and independent auditing that can prove it.

The tradeoff: speed, without blank-check consent

CMS points to “strict guardrails,” including data privacy and security standards, outcome reporting, and quality requirements. Good. But guardrails must be legible to the public and enforceable in daylight.

Use the extra runway before May 15, 2026 and July 5, 2026 for plain-language privacy rules, strong contractual limits on data use, independent security assessments, and public reporting when things go wrong. Congress should ask the boring questions about retention, access logs, secondary uses, enforcement, and remedies. Watchdogs should FOIA the fine print until it is no longer fine.

We can modernize. We can even kill the clipboard. Just do not replace it with a quiet consent trap and a fast-moving data pipeline.

Federal notices are never loud, but they do have a talent for changing the room temperature. One calendar entry, one committee meeting, and suddenly the folding chairs at the town hall start scraping.

What the FDA scheduled, and why people care

This week, the Food and Drug Administration set dates for its Pharmacy Compounding Advisory Committee to meet on July 23 and 24, 2026. The question on the table: whether certain peptides should be allowed back into the compounding pipeline.

These are not FDA-approved drugs. They are widely promoted in the wellness world, living in the gap between “promising” and “proven,” where marketing often outruns evidence.

The seven peptides under discussion

According to the FDA’s advisory committee listing, the July meeting will cover seven substances across two days:

• July 23: BPC-157, KPV, TB-500, MOTs-C
• July 24: emideltide (also called DSIP), Semax, Epitalon

The FDA listing also describes the uses it reviewed for each nomination. That is not an endorsement, but it is a procedural signal that the agency is moving from “no” to “let’s debate the terms.”

Context: compounding, pressure, and a familiar loophole risk

STAT reports that in 2023 the FDA removed 19 peptides from the list of substances compounding pharmacies could produce, and that this July panel will consider adding back seven of them. AP reports these peptides are popular, unapproved therapies pushed by wellness influencers and some political figures, and that the FDA’s move follows repeated pledges by Health and Human Services Secretary Robert F. Kennedy Jr. to loosen regulations on peptides.

Compounding can be a lifeline when patients need customized formulations. It can also become a soft underbelly of oversight, where “tailored care” quietly starts functioning like unregulated manufacturing.

The Orwell check: when “access” means fewer guardrails

“Access” is a friendly word. In health policy, it can also mean lowering the evidentiary bar and outsourcing the risk to patients while calling it empowerment. AP’s reporting captures the tension: these products are pitched for a wide range of goals online, while safety data and evidence are thin for many uses.

The tradeoff, the liberty ledger, and the Paine test

We buy speed when compounding expands. We pay with clarity about safety and effectiveness, and with accountability when something goes wrong. STAT also reports another meeting is expected before the end of February 2027 to consider additional peptides, which suggests this is a direction, not a one-off.

The liberty question is not “do we ban everything weird.” It is: who gets more freedom, and who absorbs the uncertainty about dosing, purity, contamination risk, and exaggerated claims? Paine’s simpler version: does this expand liberty for ordinary people, or concentrate power among sellers, promoters, and political appointees who can move markets with a wink?

Guardrails that should be non-negotiable

If access expands, guardrails should strengthen: rigorous public quality standards, clear disclosure that products are not FDA-approved, enforced adverse-event reporting, and real oversight of clinics marketing biologically active compounds like miracle apps. Otherwise “freedom” becomes a sales pitch with a flag on it, and patients become the test subjects again.

I was in the library this morning, that quiet little republic of paper and rules, when the news arrived like a stapled packet from a committee room at midnight: Medicare is welcoming a small army of tech-enabled care outfits into older Americans’ daily lives. It is modernization with a friendly interface and a long permissions screen.

I am not allergic to progress. Chronic disease care in the United States still runs on fax machines, hold music, and exhausted patients trying to keep track of which “little white pill” is the other little white pill. If digital support reduces friction, that is not hype. That is dignity.

What CMS is doing

CMS says more than 150 organizations have been accepted for the launch of the Medicare ACCESS model, short for Advancing Chronic Care with Effective, Scalable Solutions. The model is voluntary, runs for 10 years, and is scheduled to launch July 5, 2026. CMS extended the initial application deadline to May 15, 2026, and says later applicants may start January 1, 2027.

The pitch is simple: technology-supported care for chronic conditions that affect more than two-thirds of people with Medicare, including high blood pressure, diabetes, chronic pain, and depression. Coverage also describes monthly payments tied to outcomes, not just activity, meaning Medicare is trying to pay for better health rather than better marketing.

CMS also notes that most accepted organizations have not previously served Medicare beneficiaries. That can mean competition. It can also mean new cooks entering the kitchen right before dinner.

The tradeoff: less waiting room, more data exhaust

Here is the bargain CMS is asking the public to consider: fewer waiting rooms and more support between visits, in exchange for more data exhaust. Wearables, apps, remote monitoring, asynchronous check-ins, AI triage tools, and outcome dashboards generate information with real value. If you doubt that, check the business models of the modern internet.

So this is not just a money question. It is a “who gets the map of your life” question: your body, routines, moods, habits, and adherence patterns, plus how long that map is kept and who else gets a copy. Medicare is not a lifestyle brand. It is a public trust.

The liberty ledger and the Orwell check

On the plus side of the liberty ledger: beneficiaries gain options and access; providers gain tools to keep patients stable between visits; and CMS gains a results-oriented approach that budget analysts tend to treat like a religious experience.

On the minus side: digital chronic care can become a one-way mirror where the patient is visible and the system is opaque. People may not know which vendor collects what, which subcontractors process it, and what happens if they want to stop but cannot cleanly untangle their data from the machinery.

Run the Orwell check on the language and it practically purrs: ACCESS, scalable solutions, outcome-aligned payments, patient-centered. Nice words can still conceal power transfers. CMS does include an important reminder that inclusion on the accepted list is not an endorsement and does not guarantee participation. Good. Keep that skepticism in print.

The Paine test: liberty or concentrated power?

The Paine test is whether ACCESS expands freedom for beneficiaries or concentrates power in a new stack of contractors, platforms, and gatekeepers. If it makes care easier while keeping patients in charge of their information, it is a liberty win. If it normalizes always-on collection and makes opting out a maze, that is not modernization. It is perimeter fencing around a public benefit.

CMS says guardrails exist: enrollment and licensure requirements, privacy and security standards, outcome reporting, and quality standards, plus alignment from private payers representing 165 million members across Medicare Advantage, Medicaid, and commercial coverage. Fine. Now make the limits legible, enforced, and measurable, with results ordinary people can understand.

So here is the question I would put on the front page, not in the footnotes: if Medicare is going to modernize chronic care, what specific privacy and oversight limits would you demand before you click “I agree”?

I grew up thinking government paperwork should behave like a library card: a little effort once, then you get access without a hall monitor trailing you between the shelves.

This new Medicaid work requirement feels like the opposite. Not a card, a monthly check-in. And the most familiar part is the smell of it: policy first, guardrails later, and a lot of people told the hard part is “just administration.”

What states are waiting for

Reuters reported on April 13 that states and insurers still lack key details needed to implement a national Medicaid work requirement slated to take effect next year. The report also warns that federal implementation funding may not cover what states will actually need to build.

CMS told Reuters it is distributing funds and will provide additional guidance through an interim final rule, but detailed answers on exemptions, qualifying volunteer work, and documentation are not expected until June. That is a real problem in systems where definitions are the policy.

The Orwell check: “community engagement” is still conditional coverage

When a program is renamed to sound friendlier, I do the Orwell check. CMS has used the phrase “community engagement requirements” and framed the policy as connecting able-bodied adults to work and engagement opportunities, with states required to implement by January 1, 2027.

Translated: prove you worked, volunteered, or qualify for an exemption, or coverage can be denied or terminated. That is not encouragement. It is conditionality.

The liberty ledger: who pays, who shrugs

States inherit a surveillance chore: verification systems, reporting channels, notices, appeals, and the inevitable glitch parade. Officials described technology costs that may exceed federal funding.

Insurers brace for a messy rollout. Coverage “churn” can be priced and processed. Families do not experience churn as a spreadsheet event.

Enrollees lose time and privacy. The Commonwealth Fund explains the basic mechanics: people subject to the policy must document 80 hours a month of work or approved activity, with exemptions for groups like pregnant people and people with disabilities, and states must verify compliance at application and at least every six months. The explainer also notes CMS guidance is expected by June 2026.

KFF’s summary of the 2025 reconciliation law’s Medicaid provisions describes new administrative requirements, including updating contact information using data sources and sharing information for eligibility integrity purposes. More linkages mean more places for error, misuse, or breach.

Guardrails before the first termination notice

• Uniform minimum standards for exemptions, verification, and plain-language notices people can actually understand.
• Hard privacy rules: data minimization, short retention, audit trails, and real penalties for misuse.
• Public churn and error reporting, state by state, so “implementation challenges” do not become a euphemism for preventable coverage loss.
• Serious due process: quick, usable appeals, and terminations treated like the deprivation they are.

If the rulebook is not ready until June, who exactly is supposed to feel secure about January?

I read the inflation report the way I read a court docket: close up, suspicious of the fine print, and aware that a tidy headline can hide a messy reality.

BLS: prescription drug prices fell 1.5% in March, even as overall inflation jumped

The Bureau of Labor Statistics reported the CPI for All Urban Consumers rose 0.9% in March (seasonally adjusted) and was up 3.3% over the past year. Energy did the heavy lifting: energy rose 10.9% in March, with gasoline up 21.2%. That is the kind of spike that makes household budgets flinch.

Inside the same release, the medical care index decreased 0.2% in March, and the prescription drugs index decreased 1.5%. Meanwhile, physicians’ services rose 0.7% and hospital services rose 0.4%. Over the past year, the medical care index was up 3.1%.

So yes, there is good news. But it comes with the usual American paperwork attached.

Why a CPI win often does not feel like a win at the pharmacy counter

A national index can say prices fell while the pharmacy checkout still feels like a toll booth with a rotating cast of collectors. That is not a conspiracy. That is system design.

• The CPI is broad. It is not your receipt.
• It misses lived friction. It does not capture a drug getting bumped into a “please file an appeal” tier.
• It misses cost-shifting. Out-of-pocket costs can still rise depending on deductibles, formularies, network rules, and other fine print.

That is why a 1.5% monthly decline can coexist with people still paying the same or spending hours untangling coverage decisions.

The Orwell check: when the system calls a surcharge a “rebate”

Listen to the language. In health care, a barrier becomes a “safeguard,” a delay becomes “utilization management,” and money padded upstream becomes a “rebate” downstream. Everyone will claim the drug-price dip as proof their preferred machine works. Almost nobody will make the money trail legible.

The liberty ledger and the Paine test

Who gains freedom when drug prices fall? Patients, employers, taxpayers. Who loses freedom when the system stays opaque? Patients who cannot predict costs, doctors whose judgment gets second-guessed, families forced into rationing by finances rather than medicine.

The Paine test is simple: do lower prices expand liberty in real life, or do savings ricochet around the system while power stays concentrated in a locked room?

Guardrails that make relief real

If prices are easing, make the relief legible and durable:

• Sunlight: clearer disclosure of where drug spending goes, in plain language ordinary people can read.
• Competition: treat consolidation and contract games that block lower prices like a hidden tax on the sick.
• Privacy: modernize the plumbing without turning medical data into a temptation for overreach.

Congress, agencies, courts, and voters all have roles here: oversight that survives audits, rules that are narrow and reviewable, due process when coverage decisions become medical decisions. I’ll take the CPI’s 1.5% drop. I’m just not applauding until Americans stop paying a confusion premium for the privilege of staying alive.

I have seen this play before: a windowless committee room, coffee that tastes like toner, and a surveillance idea introduced as “modernization.” Paper shuffles. Acronyms march. Someone says “oversight” like it is a lullaby. And then your private life becomes a spreadsheet with a federal logo.

This time, the plot lands in health care. The Office of Personnel Management (OPM) is seeking ongoing access to detailed, identifiable health-claims data tied to federal workers, retirees, and their families. If you are among the more than 8 million people covered under the Federal Employees Health Benefits (FEHB) and Postal Service Health Benefits (PSHB) programs, this is not abstract. It is your prescriptions, your diagnoses, and the map of your bad days.

What OPM is asking for

Reported by CBS News and KFF Health News, OPM’s notice would require 65 insurance carriers to send monthly claims-level data to OPM, plus quarterly manufacturer rebate data. The notice labels the collection “service use and cost data,” and describes categories including medical claims, pharmacy claims, encounter data, and provider data.

CBS reports the notice did not instruct insurers to remove identifying details. Multiple experts told CBS they read the request as aiming for identifiable data, not merely de-identified trend lines.

OPM argues the goal is oversight and affordability. In its Paperwork Reduction Act notice, it cites HIPAA’s health oversight pathway as a basis for carriers to disclose protected health information to an oversight agency for authorized oversight activities.

CBS also reports the notice was posted and sent to insurers in December, comments closed in March, and OPM had not provided an update as of the report.

The Orwell check: “service use and cost data” is a euphemism

Translate the phrase. Claims data can reveal what treatment you sought, where you got it, how long the visit was, and which drugs you filled. Calling that “service use and cost data” makes a life story sound like printer ink.

The Paine test: liberty vs. centralized power

The Paine test is simple: does this expand liberty or concentrate power? Centralizing identifiable health information concentrates power. Even if today’s intent is good, the tool can be misused in politics, abused by a future administration, or breached by criminals.

CBS reports legal and policy experts raised concerns about whether the justification is specific enough under HIPAA standards, including the “minimum necessary” principle. That is not a nitpick. That is the bargain.

The liberty ledger and the tradeoff

Potential benefit: OPM gets a powerful dataset to analyze costs, utilization, and plan performance, which in theory could help push down waste and improve pricing.

Real cost: Enrollees take on risk. Identifiable claims data is leverage and exposure. Carriers also face compliance pressure and potential liability if information is shared and later breached, as CBS reports.

OPM’s published privacy materials on its Research and Oversight Repository (ROVR) describe using record-level identifiable data to build person-level longitudinal records across years and across plan changes, and note such data is generally not used for a specific individual except in cases like suspected fraud, waste, or abuse.

And one fact belongs in the header of every memo: CBS notes that in 2015 OPM disclosed a massive breach in which personal records of roughly 22 million people were stolen.

If OPM wants the vault keys, it should earn them in plain language: why identifiable data is necessary, how the collection is minimized, and what independent audits, strict access controls, logging, and retention limits will actually be enforced.

I have read enough government rate notices to recognize the vibe: warm copier toner, cold confidence, and a strong belief the public will not ask follow-up questions.

CMS released its Calendar Year 2027 Medicare Advantage and Part D Rate Announcement. Wall Street heard “more money.” Seniors heard “please do not change my plan again.” Taxpayers heard a familiar tab opening, payable on demand.

The headline number: 2.48% and about $13 billion

CMS says the finalized Medicare Advantage payment policies are projected to produce a net average increase of 2.48%, or over $13 billion in additional payments to Medicare Advantage plans in 2027.

CMS also says that if you account for the expected risk score trend in Medicare Advantage, driven by population changes and coding practices, the overall increase comes out to 4.98%.

Markets did what markets do. A Reuters report noted major insurer stocks jumped on April 7 after the announcement, with UnitedHealth, Humana, CVS, and Elevance moving up.

What changed (and what did not)

The real story lives in the fine print, where CMS tries to talk about integrity without picking a fight with every plan that has mastered the art of turning diagnoses into revenue.

• Risk adjustment model: CMS is continuing to use the 2024 Medicare Advantage risk adjustment model for 2027. It is not moving to the updated model it proposed in the advance notice, which would have been calibrated with more recent Original Medicare data. CMS frames this as giving the market more time to adjust after the phase-in of the 2024 model.
• Chart reviews: Starting in 2027, CMS is excluding diagnosis information from unlinked chart review records (diagnoses not tied to a specific encounter) from risk score calculations, with an exception for beneficiaries who switch from one Medicare Advantage organization to another.
• Audio-only: CMS is also finalizing the exclusion of diagnoses from audio-only encounters for risk score calculation.

The tradeoff: stability vs. clean receipts

Medicare Advantage is sold as choice. Sometimes it is. Sometimes it is a maze of prior authorization, narrow networks, and benefits that sparkle in October and quietly dim by March.

My centrist reality check: in a system serving tens of millions of older Americans, you cannot treat payment policy like a political mood ring. Wild swings invite plan exits and benefit cuts. But you also cannot keep sending more public money into a system if the oversight tools look like a 1997 civics textbook trying to regulate a 2026 revenue analytics department.

The Orwell check

CMS says the announcement “strengthens accountability” and supports “long-term sustainability.” Fine phrases. The question is whether they come with proof the public can actually see.

The liberty ledger

Seniors may gain stability. Plans and shareholders may gain, too. Taxpayers risk paying more without a clear, public, plan-by-plan receipt connecting dollars to outcomes. And when access to care depends on opaque internal processes and an appeal a senior does not know how to file, power is concentrated, not shared.

Guardrails before the next bump

If Medicare Advantage is getting paid more in 2027, the public should demand transparency that is readable, due process that is real, and oversight that people can trust. More money should come with more proof, out loud.

I found this story the way I find too many lately: in the paperwork. Under fluorescent lights, when a government building feels less like a public square and more like a library that lost its patience. The paper trail is the point now. Not the patients. Not the doctors. The forms.

What HHS says it is doing

This week, the Department of Health and Human Services (HHS), through its Office for Civil Rights (OCR), announced it is investigating thirteen states over abortion coverage mandates under the Weldon Amendment, a federal conscience provision tucked into spending law.

HHS OCR says it is investigating: California, Colorado, Delaware, Illinois, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Vermont, and Washington. The claim is not that these states banned abortion. The claim is that their insurance rules coerce certain health care entities to cover or pay for abortion against conscience, and that this coercion is discrimination barred by the Weldon Amendment.

The interpretation shift

HHS also says it has repudiated a prior (2021) position that excluded employers and plan sponsors from the set of protected “health care entities,” and it warned states not to rely on that older reading. Translation: the administration is widening who can claim the conscience shield, and it is doing it through a civil rights office with investigatory tools that can make your life expensive while the meaning of the law gets “clarified.”

What happened, in plain English

States regulate insurance. Some states require state-regulated plans to cover abortion (sometimes with limits around cost-sharing). The Weldon Amendment, meanwhile, is designed to stop governments from punishing certain health care entities because they will not pay for or cover abortion.

Now the federal government is telling those states: your mandate might be illegal if it does not leave enough room for opt-outs by insurers, plans, and potentially employers or sponsors. The next steps are investigations and information requests. This is not a courtroom ruling yet. It is a federal power move with an intake form.

The Orwell check:

When an agency calls something a “civil rights investigation,” I do the Orwell check. Are we protecting the weak from the strong, or handing the strong a nicer vocabulary for control? “Conscience protection” can mean defending a clinician from being forced into a procedure. It can also mean giving institutions and insurance intermediaries a policy veto that patients experience as a denial, a delay, or a surprise bill.

The Paine test and the liberty ledger

The Paine test: does this expand liberty, or concentrate power? If state mandates are too blunt, that is a real concern. But if the federal response is investigatory leverage to overrule state insurance policy, admit the purchase: centralized power.

Liberty ledger: plans, insurers, and possibly employers or sponsors gain room to refuse participation. Patients in those thirteen states risk losing uniform coverage promised under state law, even if abortion remains legal there. And the quiet loser is the public, watching major health policy swing on administrative interpretations.

So here is my question: if your health plan is going to be the battlefield for this conscience war, what guardrail would you demand first, and from which level of government?

I was raised to trust a library more than a podium. Libraries are where claims go to get cross-examined. Podiums are where claims go to get applause. So when Washington announces it has found a new cure for what ails us, I reach for my pencil, not my heart. In the committee-room air of American public health, every reform arrives wearing a friendly name tag and carrying a quiet tool belt.

This week, that tool belt is labeled nutrition. Which is not crazy. Chronic disease is eating the country alive, and we have trained doctors to memorize molecules while treating food like a lifestyle hobby. Still, in a town where power never met a good idea it could not franchise, I keep one question on the clipboard: are we improving medicine, or centralizing it?

What HHS and Education announced

On March 5, the Department of Health and Human Services and the Department of Education announced an initiative to increase nutrition education in medical schools, pointing to commitments from 53 medical schools across 31 states. The target is at least 40 hours of nutrition education, or a 40-hour competency equivalent, beginning in fall 2026. HHS also said it will dedicate $5 million through a multi-phase National Institutes of Health nutrition education challenge, and that Public Health Service officers will be required to complete nutrition-focused continuing education hours as part of their career development.

The Association of American Medical Colleges framed this as recognition of ongoing work and a push to embed evidence-based nutrition education across training. STAT reported participating schools agreed to steps such as assessing current curriculum, naming a faculty champion, and creating a public landing page describing how they will reach the 40-hour mark by fall 2026.

The Orwell check: “voluntary” and the hand on the doorknob

The administration has been careful to say this is not the federal government dictating a medical curriculum. That sentence is doing a lot of work.

The Washington Post reported HHS officials stressed the agreements are not mandatory and the event was celebratory, while also noting Secretary Robert F. Kennedy Jr. previously suggested schools without nutrition programs could risk losing federal funding, and that HHS directed medical education organizations to submit plans on embedding nutrition education efforts. The carrot is out front, but the stick has been publicly admired.

The Paine test and the liberty ledger

• What expands liberty: better training could mean more competent, practical nutrition counseling and less of the shrug-and-printout routine.
• What concentrates power: federal muscle near curricula, even in a salad-bar tie, invites definition fights over what counts as “evidence-based” and what “competency equivalent” really means.
• Who gets leaned on: schools that rely heavily on federal dollars, where autonomy can become a polite fiction.
• What else is at risk: trust, if nutrition education becomes another culture-war trench line.

The tradeoff: prevention, yes. Curriculum control, no.

I can hold two thoughts at once: nutrition belongs in medical training, and power needs guardrails. If this is truly voluntary, prove it with guardrails: publish criteria for “competency equivalent,” keep the NIH challenge insulated from political loyalty tests, make curriculum resources open, peer-reviewed, and auditable, and put in writing that schools will not be punished for good-faith disagreement so long as they can demonstrate outcomes and evidence-based instruction.

Nutrition education is a good idea. The question is whether we can accept a good idea without accepting a new lever of centralized control.